What Is Drawing Fresh Attention To Novavax (NVAX)?
Novavax (NVAX) is back in focus after its latest quarterly report showed revenue of US$56.7 million and a swing from profit to a net loss, along with a new US$82.5 million shelf registration filing.
See our latest analysis for Novavax.
The latest results and shelf registration have landed against a mixed backdrop for Novavax, with the 1-day share price return down 1.11% but the year-to-date share price return up 12.90%, while the 1-year total shareholder return has declined 17.10%.
If you are reassessing vaccine and biotech exposure after Novavax's move, it can help to compare other healthcare names using a focused screener such as 41 healthcare AI stocks
After Novavax's post earnings pullback and a share price of US$8.05 that sits well below the average analyst target of about US$14, the real puzzle is where fair value lies within that wide range of estimates.
Most Popular Narrative: 41.6% Undervalued
With Novavax trading at $8.05 against a narrative fair value of $13.78, the gap between current pricing and modeled assumptions is hard to ignore.
The analysts have a consensus price target of $12.5 for Novavax based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $25.0, and the most bearish reporting a price target of just $6.0.
Want to see what sits behind that wide spread of views on Novavax? The narrative leans heavily on future earnings, margin rebuild, and a rich profit multiple that depends on those forecasts lining up.
Result: Fair Value of $13.78 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the narrative around Novavax can quickly shift if partner led milestones slip, or if COVID vaccine demand and pricing come in weaker than analysts assume.
Find out about the key risks to this Novavax narrative.
Next Steps
If the mixed signals around Novavax leave you unsure, take a closer look at the data now and shape your own view using the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Novavax?
If Novavax has sharpened your focus on risk and reward, consider broadening your watchlist with stock ideas that fit different goals, timeframes, and comfort levels.
- Explore potential high growth opportunities early by reviewing 21 elite penny stocks with strong financials before they draw wider market attention.
- Reinforce your core holdings with companies that pair quality fundamentals with attractive pricing through the 52 high quality undervalued stocks.
- Adjust your portfolio toward companies with steadier profiles using the 80 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com